This project shows that the initial RA treatments of TNF-alpha inhibitors combined with MTX and of IL6R (as monotherapy or in combination) are effective, efficient, and safe, with data for effectiveness that in some cases surpasses csDMARD results [18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34]. The gene discussed is IL6R; the disease is rheumatoid arthritis.